Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...

Azacitidine plus venetoclax (Venclexta) demonstrated significantly improved event-free survival (EFS) vs intensive induction chemotherapy in patients with acute myeloid leukemia (AML), according to ...

Regarding safety, any-grade adverse events occurred in 100% and 99% of patients on epcoritamab plus R 2 and R 2 alone, with grade 3 or higher AEs at 90% and 68%, respectively. Serious AEs occurred in ...

Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...

Epcoritamab combined with R-mini-CHOP showed a 93% overall response rate in elderly DLBCL patients, with 86% achieving complete response. At two years, 79% of patients remained in response, and 90% ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Outcomes at one year demonstrated that high-degree mismatching did not adversely affect patient survival when PTCy was ...

KRd regimen significantly improved PFS over VRd in newly diagnosed multiple myeloma, reducing progression or death risk by 43%. Consistent benefits of KRd were observed across cytogenetic subgroups, ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...

Oncology and primary care often operate in silos, leading to communication gaps and unclear roles in patient care management.

Initial data from a phase 2 (NCT05256290) clinical trial show that silevertinib yields robust antitumor activity and ...